NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors Meeting Abstract
| Authors: | Chung, V.; Kochenderfer, M. D.; Natarajan, N.; Williams, G. R.; Laursen, A. A.; Cockrum, P.; Rhodes, W.; Surinach, A.; Zhang, L.; Li, J.; Maxwell, F.; O'Reilly, E. M.; Wainberg, Z. A.; Zervoudakis, A. |
| Abstract Title: | NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-10 |
| Start Page: | LBA4175 |
| Language: | English |
| ACCESSION: | WOS:001511766000001 |
| DOI: | 10.1200/JCO.2025.43.17_suppl.LBA4175 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
789O'Reilly -
33Zervoudakis
Related MSK Work